University of Groningen

Easy Synthesis of Two Positional Isomeric Tetrazole Libraries

Wang, Yuanze; Patil, Pravin; Dömling, Alexander

Published in:
 Synthesis

DOI:
[10.1055/s-0035-1562435](https://doi.org/10.1055/s-0035-1562435)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
 Publisher's PDF, also known as Version of record

Publication date:
 2016

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Wang, Y., Patil, P., & Dömling, A. (2016). Easy Synthesis of Two Positional Isomeric Tetrazole Libraries. *Synthesis*, 48(21), 3701-3712. <https://doi.org/10.1055/s-0035-1562435>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Easy Synthesis of Two Positional Isomeric Tetrazole Libraries

Yuanze Wang¹Pravin Patil¹

Alexander Dömling*

University of Groningen, Department of Drug Design,
A. Deusinglaan 1, 9713 AV Groningen, The Netherlands
a.s.s.domling@rug.nl

Received: 04.04.2016

Accepted after revision: 03.05.2016

Published online: 21.06.2016

DOI: 10.1055/s-0035-1562435; Art ID: ss-2016-t0232-op

Abstract A fast and efficient synthesis of libraries of positional isomeric 1H-tetrazoles and 5H-tetrazoles, for the purpose of testing binding hypothesis of isomeric tetrazoles in fragment-based drug discovery, is described.

Key words 1H-tetrazole, 5H-tetrazole, cyanoacetamide, isocyanoacetamide, [2+3] cycloaddition, Oliveri-Mandala and Alagna reaction, fragment-based drug discovery

Monosubstituted tetrazoles can exist as two isomers, the 1- and the 5-substituted form. The 1-substituted form has a mobile hydrogen and comprises a tetrazole acid with similar pKa as the carboxylic acid. The 5-substituted form, however, is charge neutral and has no mobile hydrogen. At present, there are 3 neutral and 55 negatively charged tetrazole structures in the protein data bank (PDB).² Both forms are expected to interact differentially with protein receptors (Figure 1).³ To have a testable library of both isomers we decided to synthesize a small library of compounds of both isomers each based on some previously published synthetic work of us. These libraries will be useful in fragment-based drug discovery to test binding hypothesis.⁴

We have recently described two complementary straightforward ways for the diverse synthesis of libraries of cyano- and isocyanoacetamides, by simply reacting the corresponding cyano- and isocyanoacetyl methyl esters solventless with a primary or secondary amine.⁷ Advantageously, the products in most cases precipitate and simple filtration affords very pure products. Here we describe their conversion into libraries of corresponding positional isomeric tetrazoles (Scheme 1).

Figure 1 Examples of characteristic receptor-tetrazole binding modes found in the PDB. Above: Sterol 14α-demethylase (CYP51) from *Trypanosoma cruzi* in complex with the 1-tetrazole derivative VT-1161 (PDB ID 5AJR) exhibiting the metal ligand character of tetrazoles;⁵ Below: CTX-M-9 class A β-lactamase complexed with NH-tetrazole (PDB ID 3G34) exhibiting a hydrogen contact to water and one hydrogen contact to Gln-188 side chain amide.⁶

5-Substituted 1H-tetrazoles can be synthesized by the simple [2+3] cycloaddition of nitriles to an azide.⁸ Initially, the formation of 1H-tetrazoles from the cyanoacetamides was tested, using various metal catalyst along with the solvents like DMF and DMSO under vigorous reaction conditions.⁹ Unfortunately, multiple product formations was ob-

Scheme 1 Synthetic strategy towards otherwise identical positional libraries of 1*H*-tetrazoles (red) and 5*H*-tetrazoles (blue)

served and it was difficult to isolate the pure product. Furthermore, under the microwave conditions^{9e} we failed to obtain pure products.

The use of solvents play an important role in such type of reactions.¹⁰ First, the synthesis of tetrazole **2a** was tested in various solvents such as toluene, DMF, DMSO, and acetonitrile at various reaction times (6 to 24 h) and temperatures from 55 to 160 °C using sodium azide (1.3 equiv) and ammonium chloride as well as trialkylamine hydrochloride salt (Scheme 2).

Scheme 2 Optimized conditions for the synthesis of 5-substituted 1*H*-tetrazoles

We observed that using the combination of trimethylamine hydrochloride in toluene at 90 °C afforded the product with best conversion and yield. Particularly, the reaction of *N*-benzyl-2-cyanoacetamide (**1a**) with sodium azide (3 equiv) and triethylamine hydrochloride salt (3 equiv) heated in toluene at 90 °C for 20 hours gave the product *N*-benzyl-2-(1*H*-tetrazol-5-yl)acetamide (**2a**) in 67% yield. In this method, the product could be isolated by simple aqueous workup followed by filtration, and tedious purifications were not required. The optimized protocol was examined for various *N*-alkyl-substituted 2-cyanoacetamides to study the scope and generality of the reaction condition to obtain various 5-substituted 1*H*-tetrazoles (Table 1).

Table 1 Synthesis of *N*-Substituted 2-(1*H*-Tetrazol-5-yl)acetamides

Entry	Product 2	Yield (%) ^a	Entry	Product 2	Yield (%) ^a
1		67	12		56
2		74	13		89
3		79	14		21
4		86	15		65
5		64	16		55
6		70	17		77

Table 1 (continued)

Entry	Product 2	Yield (%) ^a	Entry	Product 2	Yield (%) ^a
7		76	18		98
8		70	19		25
9		87	20		51
10		93	21		9
11		70	22		25

^a Isolated yield.

Tetrazole derived from *N*-phenethyl-2-cyanoacetamide (**1b**) gave *N*-phenethyl-2-(1*H*-tetrazol-5-yl)acetamide (**2b**) in even better yield (74%) than **2a** (67%). A similar trend of increasing yields were observed as the carbon chain length of *N*-alkylphenyl in 2-cyanoacetamides increased from 3 to 4, for example, *N*-phenpropyl-2-(1*H*-tetrazol-5-yl)acetamide (**2c**) and *N*-phenbutyl-2-(1*H*-tetrazol-5-yl)acetamide (**2d**) were obtained in 79% and 86% yield, respectively. When the *N*-benzyl group of 2-cyanoacetamide was replaced with various substituted *N*-benzyl groups **1e–h**, the yields of products **2e–h** were similar. Remarkably, in the case of the highly electron rich *N*-(3,4-dimethoxyphenyl)-2-cyanoacetamide (**1j**), *N*-(3,4-dimethoxyphenyl)-2-(1*H*-tetrazol-5-yl)acetamide (**2j**) was obtained in excellent yield (93%). Furthermore, simple *N*-alkyl-substituted 2-cyanoacetamides **1q–r** gave good yield of products **2q–r**. However, *N*-allyl-2-cyanoacetamide (**1s**) was found to be less reactive and gave *N*-allyl-2-(1*H*-tetrazol-5-yl)acetamide (**2s**) in only 25% yield. Unfortunately, *N,N*-disubstituted 2-cyanoacetamides **1u,v** in the same reaction conditions gave poor yields of **2u,v** as 9% and 25%, respectively.

Noteworthy, the herein described method does not require any expensive organometallic reagents as well as harsh reaction conditions such as very high reaction temperature or microwave irradiation.

Scheme 3 Optimized conditions for the synthesis of 1-substituted 5*H*-tetrazoles**Table 2** Optimization of *N*-Benzyl-2-(1*H*-tetrazol-1-yl)acetamide

Azide	Solvent	Temp (°C)	Time (h)	Yield (%) ^a
NaN ₃	MeOH	25	20	11
TMSN ₃	CH ₂ Cl ₂	25	20	traces
NaN ₃	MeCN	40	20	traces
TMSN ₃	CH ₂ Cl ₂	40	20	traces
NaN ₃	CH ₂ Cl ₂	25	20	traces
TMSN ₃	MeOH	25	20	27
TMSN ₃	MeOH	55	20	45
NaN ₃	MeOH–H ₂ O (3:1)	25	20	35
TMSN ₃	MeOH–H ₂ O (3:1)	25	20	97

^a Isolated yield.

After successfully synthesizing the *N*-substituted-2-(1*H*-tetrazol-5-yl)acetamides, the synthesis of *N*-alkyl-2-(1*H*-tetrazol-1-yl)acetamide was examined by using the *N*-alkyl-2-isocyanoacetamides (Scheme 3).

Isocyanide to tetrazole conversion is also known as the Oliveri-Mandala and Alagna reaction.¹¹ The freshly prepared *N*-substituted 2-isocyanoacetamides were used as they are easily synthesized by the neat reaction of 1° or 2° alkylamines with methyl isocyanoacetate.^{7b}

Initially, the formation of the tetrazole **4a** was tested by reacting the *N*-phenethyl-2-isocyanoacetamide (**3a**) with sodium azide in methanol, as in the general Oliveri-Mandala

and Alagna reaction.¹¹ Unfortunately, poor yield (11%) was observed (Table 2). Then various solvents and azide sources were tested. By using dichloromethane as the solvent, only traces of the product formation was observed. When sodium azide was changed to trimethylsilyl azide in methanol, 27% yield was obtained at room temperature. However, the yield could be increased to 45% when the reaction was heated at 55 °C in methanol. Using 25% water in methanol as a solvent with sodium azide at room temperature gave only 35% yield of the product.

Table 3 Synthesis of *N*-Substituted 2-(1*H*-Tetrazol-1-yl)acetamides

Entry	Reactant 3	Yield (%) ^a	Product 4	Yield (%) ^a
1		85		97
	3a		4a	
2		87		95
	3b		4b	
3		85		98
	3c		4c	
4		83		97
	3d		4d	
5		86		98
	3e		4e	
6		89		86
	3f		4f	
7		90		95
	3g		4g	
8		86		86
	3h		4h	

Table 3 (continued)

Entry	Reactant 3	Yield (%) ^a	Product 4	Yield (%) ^a
9	3i	75	4i	90
10	3j	88	4j	92
11	3k	92	4k	78
12	3l	86	4l	74
13	3m	89	4m	84
14	3n	87	4n	87
15	3o	81	4o	86
16	3p	78	4p	72
17	3q	83	4q	74
18	3r	82	4r	69

^a Isolated yield.

Surprisingly, when sodium azide was replaced by trimethylsilyl azide with 25% co-solvent water in methanol at room temperature, the yield was dramatically increased to 97% (Table 2). With this optimized conditions, substrate

scope of this method was investigated for various *N*-alkyl-2-isocyanoacetamides to form *N*-alkyl-2-(1*H*-tetrazol-1-yl)acetamides (Table 3). In all cases, excellent yield of products **4a–n** (70–97%) were obtained. This method is very ef-

ficient, as we observed that all *N*-alkyl-2-(1*H*-tetrazol-1-yl)acetamides were precipitated during the aqueous work-up followed by simple filtration to afford the pure product. In few cases **4l** and **4o**, precipitation from water did not occur; in such cases, the products were obtained by extraction using a saturated solution of sodium chloride and dichloromethane. Noteworthy, with this method all the products **4a–q** were obtained in good to excellent yields. To support the fragment likeliness of our scaffolds and synthesized compounds the chemical properties MW and clogP were calculated, which are plotted in Figure 2.

Figure 2 cLogP vs Mol. weight of virtual libraries of 500 randomly generated molecules of 1*H*-tetrazoles (violet) and 5*H*-tetrazoles (blue) along with our synthesized library 1*H*-tetrazoles (green) and 5*H*-tetrazoles (red)

In conclusion, we have prepared two positional isomeric monosubstituted tetrazole libraries by a convenient and fast procedure. With mild reaction conditions, our new methods provide significant advantages such as easy work-up, short reaction time, and broad substrate scope. With more and more drug candidates originating from fragment-based lead discovery having been progressed into clinical trials, the efficient build-up of fragment libraries containing 'drug-like' fragments like tetrazole is of great importance. Further investigation of our herein-described positional isomeric tetrazole libraries in different protein targets is currently ongoing and will be reported in due course.

NMR spectra were recorded on a Bruker Avance 500 spectrometer [¹H NMR (500 MHz), ¹³C NMR (126 MHz)]. Chemical shifts for ¹H NMR were reported as δ values and coupling constants were in hertz (Hz). Standard abbreviations were used for defining spin multiplicity. Chemical shifts for ¹³C NMR reported in ppm relative to the solvent

peak. TLC was performed on Fluka precoated silica gel plates (0.20 mm thick, particle size 25 μ m). Flash chromatography was performed on a Teledyne ISCO Combiflash Rf, using RediSep Rf Normal-phase Silica Flash Columns (Silica Gel 60 Å, 230–400 mesh) and on a Reveleris® X2 Flash Chromatography, using Grace® Reveleris Silica flash cartridges (12 g). Reagents were available from commercial suppliers (Sigma Aldrich, ABCR, Acros and AK Scientific) and used without any purification, unless otherwise noted. Electrospray ionization mass spectra (ESI-MS) were recorded on a Waters Investigator Semi-prep 15 SFC-MS instrument.

5-Substituted Tetrazoles 2; General Procedure A (GP A)

To a stirred solution of *N*-alkyl-substituted 2-cyanoacetamide **1** (5 mmol) in toluene (10 mL) was added NaN₃ (3 equiv) and triethylamine hydrochloride salt (3 equiv). The reaction mixture was heated to 90 °C for 20 h. Ice-cold H₂O (25 mL) was added to the reaction mixture and acidified with aq HCl and stirred at 0 °C for 30 min. The precipitated product was collected by filtration, washed with cold H₂O (25 mL), and dried in vacuum (Table 1).

2-Isocynoacetamides 3; General Procedure B (GP B)

To the appropriate amine (10 mmol) was added methyl isocyanacetate (1 g, 10 mmol), and the mixture was stirred overnight at r.t. If the product precipitated during the reaction, it was collected by filtration, washed with cold Et₂O (3 $\times$), and dried under vacuum overnight. If no precipitation was observable, cold Et₂O was added to the reaction mixture, and the product was allowed to crystallize in the freezer at –20 °C.

1-Substituted Tetrazoles 4; General Procedure C (GP C)

To the *N*-alkyl-2-isocynoacetamide (1.0 mmol) in a mixture of solvents MeOH–H₂O (3:1, 1 M) was added trimethylsilyl azide (138 mg, 1.2 mmol) and the resulting mixture was stirred overnight at r.t. The reaction, which precipitated out was filtered and washed with cold H₂O (3 $\times$ 5 mL). The reactions which do not precipitate, were diluted with brine (1 mL) and extracted with CH₂Cl₂ (3 $\times$ 10 mL). The solvents were removed under reduced pressure to afford the pure product (Table 3).

N-Benzyl-2-(1*H*-tetrazol-5-yl)acetamide (**2a**)

The product was obtained using GP A, 8 mmol scale; yield: 1.16 g (67%); white solid; mp 166–168 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 8.83 (t, *J* = 5.9 Hz, 1 H), 7.40–7.19 (m, 5 H), 4.32 (d, *J* = 5.9 Hz, 2 H), 3.96 (s, 2 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 166.1, 151.2, 138.9, 128.3, 127.4, 126.9, 42.5, 30.5.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₁₀H₁₁N₅O: 217.10; found [M + H]⁺: 218.09.

N-Phenethyl-2-(1*H*-tetrazol-5-yl)acetamide (**2b**)

The product was obtained using GP A, 8 mmol scale; yield: 1.37 g (74%); white solid; mp 170–171 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 8.43 (t, *J* = 5.5 Hz, 1 H), 7.38–7.11 (m, 5 H), 3.87 (s, 2 H), 3.39–3.25 (m, 2 H), 2.73 (t, *J* = 7.4 Hz, 2 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 166.0, 151.2, 139.2, 128.6, 128.4, 126.2, 40.6, 35.0, 30.5.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₁₁H₁₃N₅O: 231.11; found [M + H]⁺: 232.08.

***N*-(3-Phenylpropyl)-2-(1*H*-tetrazol-5-yl)acetamide (2c)**

The product was obtained using GP A, 8 mmol scale; yield: 1.58 g (79%); white solid; mp 104–106 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 8.37 (t, *J* = 5.5 Hz, 1 H), 7.27 (t, *J* = 7.5 Hz, 2 H), 7.23–7.12 (m, 3 H), 3.88 (s, 2 H), 3.10 (q, *J* = 6.6 Hz, 2 H), 2.59 (t, *J* = 7.7 Hz, 2 H), 1.72 (quint, *J* = 7.2 Hz, 2 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 166.0, 151.3, 141.6, 128.3, 125.8, 38.5, 32.4, 30.7, 30.6.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₁₂H₁₅N₅O: 245.13; found [M – H]⁺: 244.11.

***N*-(4-Phenylbutyl)-2-(1*H*-tetrazol-5-yl)acetamide (2d)**

The product was obtained using GP A, 8 mmol scale; yield: 1.78 g (86%); white solid; mp 122–124 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 8.31 (t, *J* = 5.7 Hz, 1 H), 7.27 (t, *J* = 7.7 Hz, 2 H), 7.23–7.12 (m, 3 H), 3.86 (s, 2 H), 3.11 (q, *J* = 6.7 Hz, 2 H), 2.57 (t, *J* = 7.7 Hz, 2 H), 1.62–1.51 (m, 2 H), 1.48–1.38 (m, 2 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 165.9, 151.2, 142.1, 128.3, 128.2, 125.7, 38.7, 34.8, 30.5, 28.6, 28.3.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₁₃H₁₇N₅O: 259.14; found [M – H]⁺: 258.16.

***N*-[1-(4-Chlorophenyl)ethyl]-2-(1*H*-tetrazol-5-yl)acetamide (2e)**

The product was obtained using GP A, 8 mmol scale; yield: 1.37 g (64%); white solid; mp 182–184 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 8.84 (d, *J* = 7.8 Hz, 1 H), 7.51–7.26 (m, 4 H), 5.00–4.83 (m, 1 H), 3.95 (s, 2 H), 1.38 (d, *J* = 7.0 Hz, 3 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 165.3, 151.1, 143.3, 131.3, 128.3, 127.9, 47.9, 30.5, 22.3, 22.2.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₁₁H₁₂ClN₅O: 265.07; found [M – H]⁺: 263.90.

2-(1*H*-Tetrazol-5-yl)-*N*-[1-(*p*-tolyl)ethyl]acetamide (2f)

The product was obtained using GP A, 4 mmol scale; yield: 0.69 g (70%); white solid; mp 187–189 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 8.75 (d, *J* = 7.9 Hz, 1 H), 7.20 (d, *J* = 7.8 Hz, 2 H), 7.13 (d, *J* = 7.8 Hz, 2 H), 4.95–4.81 (m, 1 H), 3.92 (s, 2 H), 2.26 (s, 3 H), 1.35 (d, *J* = 7.0 Hz, 3 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 165.1, 151.1, 141.1, 135.9, 128.8, 125.9, 48.1, 30.5, 22.4, 20.6.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₁₂H₁₅N₅O: 245.13; found [M – H]⁺: 244.05.

***N*-(4-Chlorobenzyl)-2-(1*H*-tetrazol-5-yl)acetamide (2g)**

The product was obtained using GP A, 3.6 mmol scale; yield: 0.57 g (76%); white solid; mp 189–191 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 7.36 (d, *J* = 8.2 Hz, 2 H), 7.26 (d, *J* = 8.2 Hz, 2 H), 6.46 (t, *J* = 6.2 Hz, 1 H), 5.57 (s, 2 H), 4.08 (d, *J* = 6.2 Hz, 2 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 158.7, 140.1, 131.0, 128.8, 128.1, 42.2, 42.1.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₁₀H₁₀ClN₅O: 251.06; found [M + Na]⁺: 274.17.

***N*-(4-Fluorobenzyl)-2-(1*H*-tetrazol-5-yl)acetamide (2h)**

The product was obtained using GP A, 8 mmol scale; yield: 1.32 g (70%); white solid; mp 171–173 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 8.85 (t, *J* = 5.9 Hz, 1 H), 7.48–7.25 (m, 2 H), 7.17 (t, *J* = 8.7 Hz, 2 H), 4.31 (d, *J* = 5.8 Hz, 2 H), 3.97 (s, 2 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 166.2, 161.31 (d, *J* = 242.6 Hz), 151.2, 135.14 (d, *J* = 2.9 Hz), 129.39 (d, *J* = 8.2 Hz), 115.11 (d, *J* = 21.2 Hz), 41.8, 30.6.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₁₀H₁₀FN₅O: 235.09; found [M – H]⁺: 233.97.

***N*-(4-Fluorophenethyl)-2-(1*H*-tetrazol-5-yl)acetamide (2i)**

The product was obtained using GP A, 8 mmol scale; yield: 1.74 g (87%); white solid; mp 159–161 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 8.41 (s, 1 H), 7.31–7.19 (m, 2 H), 7.17–7.01 (m, 2 H), 3.85 (s, 2 H), 3.30 (q, *J* = 6.8 Hz, 2 H), 2.72 (t, *J* = 7.3 Hz, 2 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 166.1, 160.90 (d, *J* = 241.5 Hz), 151.2, 135.41 (d, *J* = 3.0 Hz), 130.45 (d, *J* = 7.9 Hz), 115.01 (d, *J* = 21.0 Hz), 40.6, 34.1, 30.6.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₁₁H₁₂FN₅O: 249.10; found [M – H]⁺: 248.08.

***N*-(3,4-Dimethoxybenzyl)-2-(1*H*-tetrazol-5-yl)acetamide (2j)**

The product was obtained using GP A, 8 mmol scale; yield: 1.03 g (93%); white solid; mp 156–158 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 8.78 (s, 1 H), 6.92–6.85 (m, 2 H), 6.80 (d, *J* = 8.1 Hz, 1 H), 4.24 (d, *J* = 5.6 Hz, 2 H), 3.94 (s, 2 H), 3.73 (s, 3 H), 3.72 (s, 3 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 166.1, 151.4, 148.7, 147.9, 131.3, 119.5, 111.8, 111.5, 55.6, 45.7, 42.3, 30.6.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₁₂H₁₅N₅O₃: 277.12; found [M – H]⁺: 276.06.

***N*-(2-Hydroxy-2-phenylethyl)-2-(1*H*-tetrazol-5-yl)acetamide (2k)**

The product was obtained using GP A, 8 mmol scale; yield: 1.39 g (70%); white solid; mp 162–164 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 8.47 (t, *J* = 5.7 Hz, 1 H), 7.36–7.29 (m, 4 H), 7.28–7.21 (m, 1 H), 5.53 (s, 1 H), 4.62 (dd, *J* = 8.1, 4.4 Hz, 1 H), 3.91 (s, 2 H), 3.34 (dt, *J* = 13.4, 6.2, 4.4 Hz, 1 H), 3.15 (ddd, *J* = 13.4, 8.1, 5.2 Hz, 1 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 166.3, 151.2, 143.5, 128.1, 127.2, 126.0, 71.2, 47.2, 30.5.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₁₁H₁₃N₅O₂: 247.11; found [M – H]⁺: 246.19.

***N*-(2,2-Diphenylethyl)-2-(1*H*-tetrazol-5-yl)acetamide (2l)**

The product was obtained using GP A, 4 mmol scale; yield: 0.69 g (56%); white solid; mp 181–183 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 8.42 (s, 1 H), 7.38–7.25 (m, 8 H), 7.23–7.13 (m, 2 H), 4.18 (td, *J* = 7.8, 2.2 Hz, 1 H), 3.84–3.68 (m, 4 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 166.2, 151.1, 142.7, 128.5, 127.9, 126.4, 50.0, 43.5, 30.4.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₁₇H₁₇N₅O: 307.14; found [M – H]⁺: 306.18.

***N*-(Naphthalen-2-ylmethyl)-2-(1*H*-tetrazol-5-yl)acetamide (2m)**

The product was obtained using GP A, 8 mmol scale; yield: 1.90 g (89%); white solid; mp 213–215 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 8.89 (d, *J* = 5.6 Hz, 1 H), 8.15–8.01 (m, 1 H), 8.01–7.91 (m, 1 H), 7.87 (dd, *J* = 7.0, 2.4 Hz, 1 H), 7.65–7.35 (m, 4 H), 4.79 (d, *J* = 5.6 Hz, 2 H), 3.98 (s, 2 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 166.1, 151.3, 134.0, 133.4, 130.9, 128.6, 127.8, 126.4, 125.9, 125.8, 125.5, 123.5, 40.7, 30.5.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₁₄H₁₃N₅O: 267.11; found [M – H]⁺: 266.04.

***N*-(Furan-2-ylmethyl)-2-(1*H*-tetrazol-5-yl)acetamide (2n)**

The product was obtained using GP A, 8 mmol scale; yield: 0.35 g (21%); white solid; mp 166–168 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 8.81 (t, *J* = 5.5 Hz, 1 H), 7.59 (s, 1 H), 6.40 (d, *J* = 3.0 Hz, 1 H), 6.28 (d, *J* = 3.0 Hz, 1 H), 4.29 (d, *J* = 5.5 Hz, 2 H), 3.93 (s, 2 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 166.0, 151.7, 151.1, 142.3, 110.5, 107.3, 35.8, 30.4.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₈H₉N₅O₂: 207.08; found [M + Na]⁺: 230.12.

2-(1*H*-Tetrazol-5-yl)-*N*-[2-(thiophen-2-yl)ethyl]acetamide (2o)

The product was obtained using GP A, 8 mmol scale; yield: 1.24 g (65%); white solid; mp 150–152 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 8.50 (t, *J* = 5.7 Hz, 1 H), 7.33 (d, *J* = 5.1 Hz, 1 H), 7.00–6.79 (m, 2 H), 3.88 (s, 2 H), 3.41–3.25 (m, 2 H), 2.95 (t, *J* = 7.1 Hz, 2 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 166.2, 151.2, 141.3, 127.0, 125.3, 124.1, 40.7, 30.6, 29.1.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₉H₁₁N₅O₂: 237.07; found [M – H]⁺: 236.05.

***N*-Cyclopropyl-2-(1*H*-tetrazol-5-yl)acetamide (2p)**

The product was obtained using GP A, 8 mmol scale; yield: 0.74 g (55%); white solid; mp 173–175 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 8.41 (s, 1 H), 3.81 (s, 2 H), 2.68–2.60 (m, 1 H), 0.66–0.60 (m, 2 H), 0.45–0.38 (m, 2 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 167.1, 151.1, 30.4, 22.5, 5.6.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₆H₉N₅O: 167.08; found [M + Na]⁺: 190.05.

***N*-Butyl-2-(1*H*-tetrazol-5-yl)acetamide (2q)**

The product was obtained using GP A, 8 mmol scale; yield: 1.14 g (77%); white solid; mp 82–84 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 8.28 (s, 1 H), 3.85 (s, 2 H), 3.12–3.02 (m, 2 H), 1.46–1.34 (m, 2 H), 1.33–1.22 (m, 2 H), 0.86 (t, *J* = 7.3 Hz, 3 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 166.0, 151.2, 38.7, 31.1, 30.6, 19.6, 13.7.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₇H₁₃N₅O: 183.11; found [M – H]⁺: 182.11.

***N*-Dodecyl-2-(1*H*-tetrazol-5-yl)acetamide (2r)**

The product was obtained using GP A, 4 mmol scale; yield: 1.03 g (98%); white solid; mp 152–154 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 8.28 (d, *J* = 7.4 Hz, 1 H), 3.84 (s, 2 H), 1.45–1.15 (m, 22 H), 0.85 (t, *J* = 6.8 Hz, 3 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 165.8, 151.2, 38.9, 31.3, 30.5, 29.1, 28.9, 28.8, 26.4, 22.1, 13.9.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₁₅H₂₉N₅O: 295.24; found [M – H]⁺: 294.27.

***N*-Allyl-2-(1*H*-tetrazol-5-yl)acetamide (2s)**

The product was obtained using GP A, 8 mmol scale; yield: 0.34 g (25%); white solid; mp 140–142 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 8.49 (d, *J* = 6.0 Hz, 1 H), 5.87–5.69 (m, 1 H), 5.17 (dq, *J* = 17.2, 1.8 Hz, 1 H), 5.11–5.03 (m, 1 H), 3.91 (s, 2 H), 3.76–3.68 (m, 2 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 165.9, 151.2, 134.8, 115.5, 41.2, 30.4.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₆H₉N₅O: 167.08; found [M – H]⁺: 165.98.

***N*-Cyclohexyl-2-(1*H*-tetrazol-5-yl)acetamide (2t)**

The product was obtained using GP A, 8 mmol scale; yield: 0.85 g (51%); white solid; mp 215–217 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 8.21 (d, *J* = 7.9 Hz, 1 H), 3.84 (s, 2 H), 3.59–3.39 (m, 1 H), 1.82–1.62 (m, 4 H), 1.53 (dt, *J* = 12.3, 3.9 Hz, 1 H), 1.37–1.00 (m, 5 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 164.9, 151.2, 47.9, 32.3, 30.6, 25.2, 24.4.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₉H₁₅N₅O: 209.13; found [M – H]⁺: 208.01.

1-(Pyrrolidin-1-yl)-2-(1*H*-tetrazol-5-yl)ethan-1-one (2u)

The product was obtained using GP A, 8 mmol scale; yield: 0.13 g (9%); white solid; mp 137–139 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 4.10 (s, 2 H), 3.55 (t, *J* = 6.8 Hz, 2 H), 3.31 (t, *J* = 6.8 Hz, 2 H), 1.91 (quint, *J* = 6.8 Hz, 2 H), 1.80 (quint, *J* = 6.8 Hz, 2 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 164.6, 151.1, 46.2, 45.7, 29.9, 25.5, 24.0.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₇H₁₁N₅O: 181.10; found [M + H]⁺: 182.11.

1-Morpholino-2-(1*H*-tetrazol-5-yl)ethan-1-one (2v)

The product was obtained using GP A, 8 mmol scale; yield: 0.40 g (25%); white solid; mp 196–198 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 4.21 (s, 2 H), 3.65–3.59 (m, 2 H), 3.59–3.52 (m, 4 H), 3.50–3.43 (m, 2 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 165.4, 151.3, 66.0, 66.0, 45.7, 41.9, 28.6.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₇H₁₁N₅O₂: 197.09; found [M + H]⁺: 198.12.

***N*-Benzyl-2-isocyanoacetamide (3a)**

The product was obtained using GP B, 10 mmol scale; yield: 1.48 g (85%); white solid; mp 125–127 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 8.66 (s, 1 H), 7.35–7.24 (m, 5 H), 4.42 (s, 2 H), 4.32 (d, *J* = 5.9 Hz, 2 H).

^{13}C NMR (126 MHz, $\text{DMSO}-d_6$): δ = 163.0, 158.2, 138.6, 128.3, 127.4, 127.0, 44.8, 42.5.

***N*-(4-Fluorobenzyl)-2-isocyanoacetamide (3b)**

The product was obtained using GP B, 10 mmol scale; yield: 1.68 g (87%); white solid; mp 135–137 °C.

^1H NMR (500 MHz, $\text{DMSO}-d_6$): δ = 8.66 (s, 1 H), 7.31 (dd, J = 8.5, 5.9 Hz, 2 H), 7.15 (t, J = 8.9 Hz, 2 H), 4.40 (s, 2 H), 4.28 (d, J = 5.9 Hz, 2 H).

^{13}C NMR (126 MHz, $\text{DMSO}-d_6$): δ = 163.1, 162.3, 160.3, 158.2, 134.9, 134.9, 129.5, 129.4, 115.2, 115.0, 44.8, 41.8.

***N*-(4-Chlorobenzyl)-2-isocyanoacetamide (3c)**

The product was obtained using GP B, 10 mmol scale; yield: 1.79 g (85%); white solid; mp 122–124 °C.

^1H NMR (500 MHz, $\text{DMSO}-d_6$): δ = 8.69 (s, 1 H), 7.39 (d, J = 8.4 Hz, 2 H), 7.29 (d, J = 8.4 Hz, 2 H), 4.42 (s, 2 H), 4.29 (d, J = 5.9 Hz, 2 H).

^{13}C NMR (126 MHz, $\text{DMSO}-d_6$): δ = 163.2, 158.3, 137.8, 131.6, 129.3, 128.3, 44.8, 41.8.

2-Isocyano-*N*-(1-phenylethyl)acetamide (3d)

The product was obtained using GP B, 10 mmol scale; yield: 1.57 g (83%); white solid; mp 128–130 °C.

^1H NMR (500 MHz, CDCl_3): δ = 7.39–7.29 (m, 5 H), 6.60 (s, 1 H), 5.14 (quint, J = 7.1 Hz, 1 H), 4.15 (d, J = 8.5 Hz, 2 H), 1.56 (d, J = 6.9 Hz, 3 H).

^{13}C NMR (126 MHz, $\text{DMSO}-d_6$): δ = 163.2, 158.3, 137.8, 131.6, 129.2, 128.3, 44.8, 41.8.

2-Isocyano-*N*-(thiophen-2-ylmethyl)acetamide (3e)

The product was obtained using GP B, 10 mmol scale; yield: 1.55 g (86%); white solid; mp 97–99 °C.

^1H NMR (500 MHz, CDCl_3): δ = 7.27 (s, 1 H), 7.02 (d, J = 3.5 Hz, 1 H), 7.01 (m, 2 H), 6.80 (s, 2 H), 4.67 (d, J = 5.7 Hz, 2 H), 4.19 (s, 2 H).

^{13}C NMR (126 MHz, CDCl_3): δ = 162.5, 162.2, 139.3, 127.2, 126.9, 125.9, 45.3, 38.6.

2-Isocyano-*N*-phenethylacetamide (3f)

The product was obtained using GP B, 10 mmol scale; yield: 1.68 g (89%); white solid; mp 94–96 °C.

^1H NMR (500 MHz, CDCl_3): δ = 7.35–7.20 (s, 5 H), 6.44 (s, 1 H), 4.12 (s, 2 H), 3.59 (q, J = 6.9 Hz, 2 H), 2.87 (t, J = 7.1 Hz, 2 H).

^{13}C NMR (126 MHz, CDCl_3): δ = 162.4, 161.9, 138.1, 128.8, 128.7, 126.8, 45.2, 41.0, 35.3.

***N*-(3,4-Dimethoxyphenethyl)-2-isocyanoacetamide (3g)**

The product was obtained using GP B, 10 mmol scale; yield: 2.23 g (90%); white solid; mp 95–97 °C.

^1H NMR (500 MHz, CDCl_3): δ = 6.82 (d, J = 8.1 Hz, 1 H), 6.74 (dd, J = 8.2, 1.7 Hz, 1 H), 6.71 (d, J = 1.4 Hz, 1 H), 6.46 (s, 1 H), 4.12 (s, 2 H), 3.88 (s, 3 H), 3.86 (s, 3 H), 3.56 (q, J = 6.8 Hz, 2 H), 2.81 (t, J = 7.1 Hz, 2 H).

^{13}C NMR (126 MHz, CDCl_3): δ = 162.3, 162.2, 149.2, 148.0, 130.6, 120.7, 111.8, 111.6, 56.5, 55.9, 45.3, 41.2, 35.0.

***N*-(Cyclopropylmethyl)-2-isocyanoacetamide (3h)**

The product was obtained using GP B, 10 mmol scale; yield: 1.08 g (86%); white solid; mp 89–91 °C.

^1H NMR (500 MHz, CDCl_3): δ = 6.52 (s, 1 H), 4.14 (s, 2 H), 2.78–2.73 (m, 1 H), 0.87–0.83 (m, 2 H), 0.62–0.59 (m, 2 H).

^{13}C NMR (126 MHz, CDCl_3): δ = 163.7, 161.9, 45.2, 22.9, 8.3, 6.4.

***N*-(1-Benzylpiperidin-4-yl)-2-isocyanoacetamide (3i)**

The product was obtained using GP B, 10 mmol scale; yield: 1.94 g (75%); white solid; mp 135–137 °C.

^1H NMR (500 MHz, CDCl_3): δ = 7.32–7.26 (m, 5 H), 6.26 (d, J = 6.1 Hz, 1 H), 4.14 (s, 2 H), 3.87–3.81 (m, 1 H), 3.52 (s, 2 H), 2.84 (d, J = 11.6 Hz, 2 H), 2.15 (t, J = 11.1 Hz, 2 H), 1.92 (d, J = 12.6 Hz, 2 H), 1.60–1.52 (m, 2 H).

^{13}C NMR (126 MHz, CDCl_3): δ = 162.4, 161.6, 138.2, 129.2, 128.4, 127.2, 63.0, 52.1, 47.4, 45.4, 32.0.

***N*-Butyl-2-isocyanoacetamide (3j)**

The product was obtained using GP B, 10 mmol scale; yield: 1.24 g (88%); white solid; mp 53–55 °C.

^1H NMR (500 MHz, $\text{DMSO}-d_6$): δ = 8.11 (s, 1 H), 4.30 (s, 2 H), 3.08 (q, J = 6.9 Hz, 2 H), 1.39 (quint, J = 6.9 Hz, 2 H), 1.27 (sext, J = 7.7 Hz, 2 H), 0.87 (t, J = 7.4 Hz, 3 H).

^{13}C NMR (126 MHz, CDCl_3): δ = 162.4, 162.2, 45.4, 39.9, 31.4, 20.1, 13.8.

2-Isocyano-*N*-(prop-2-yn-1-yl)acetamide (3k)

The product was obtained using GP B, 10 mmol scale; yield: 1.13 g (92%); white solid; mp 108–110 °C.

^1H NMR (500 MHz, CDCl_3): δ = 6.66 (s, 1 H), 4.21 (s, 2 H), 4.13–4.12 (m, 2 H), 2.32–2.30 (m, 1 H).

^{13}C NMR (126 MHz, CDCl_3): δ = 162.9, 162.2, 78.2, 72.7, 45.3, 29.8.

2-Isocyano-*N*-(2-morpholinoethyl)acetamide (3l)

The product was obtained using GP B, 10 mmol scale; yield: 1.70 g (86%); white solid; mp 80–81 °C.

^1H NMR (500 MHz, $\text{DMSO}-d_6$): δ = 8.09 (s, 1 H), 4.33 (s, 2 H), 3.56 (t, J = 4.5 Hz, 4 H), 3.21 (q, J = 6.4 Hz, 2 H), 2.34 (t, J = 6.8 Hz, 6 H).

^{13}C NMR (126 MHz, CDCl_3): δ = 162.4, 162.31, 67.1, 56.3, 53.3, 45.5, 35.9.

2-Isocyano-1-(pyrrolidin-1-yl)ethan-1-one (3m)

The product was obtained using GP B, 10 mmol scale; yield: 1.24 g (89%); white solid; mp 71–73 °C.

^1H NMR (500 MHz, CDCl_3): δ = 4.21 (s, 2 H), 3.51 (t, J = 7.0 Hz, 2 H), 3.39 (t, J = 6.8 Hz, 2 H), 2.00 (quint, J = 6.8 Hz, 2 H), 1.90 (quint, J = 6.8 Hz, 2 H).

^{13}C NMR (126 MHz, CDCl_3): δ = 160.7, 160.1, 46.6, 46.2, 45.0, 26.1, 24.0.

2-Isocyano-1-(piperidin-1-yl)ethan-1-one (3n)

The product was obtained using GP B, 10 mmol scale; yield: 1.33 g (87%); white solid; mp 84–86 °C.

^1H NMR (500 MHz, CDCl_3): δ = 4.27 (s, 2 H), 3.56 (t, J = 5.6 Hz, 2 H), 3.31 (t, J = 5.5 Hz, 2 H), 1.68–1.55 (m, 6 H).

^{13}C NMR (126 MHz, CDCl_3): δ = 160.6, 160.5, 46.5, 44.5, 43.6, 26.0, 25.2, 24.1.

2-Isocyano-1-morpholinoethan-1-one (3o)

The product was obtained using GP B, 10 mmol scale; yield: 1.26 g (81%); brown solid; mp 69–71 °C.

¹H NMR (500 MHz, CDCl₃): δ = 4.30 (s, 2 H), 3.70–3.66 (m, 4 H), 3.61 (t, *J* = 4.9 Hz, 2 H), 3.37 (t, *J* = 4.8 Hz, 2 H).

¹³C NMR (126 MHz, CDCl₃): δ = 161.4, 161.2, 66.6, 66.2, 45.9, 44.4, 42.8.

1-(4-Benzylpiperazin-1-yl)-2-isocyanoethan-1-one (3p)

The product was obtained using GP B, 10 mmol scale; yield: 1.91 g (78%); white solid; mp 80–82 °C.

¹H NMR (500 MHz, CDCl₃): δ = 7.30 (m, 5 H), 4.27 (s, 2 H), 3.65 (t, *J* = 4.8 Hz, 2 H), 3.53 (s, 2 H), 3.40 (t, *J* = 4.7 Hz, 2 H), 2.49–2.46 (m, 4 H).

¹³C NMR (126 MHz, CDCl₃): δ = 161.3, 160.8, 137.3, 129.1, 128.4, 127.4, 62.7, 52.5, 52.4, 45.7, 44.4, 42.6.

N-(4-Chlorobenzyl)-2-isocyano-4-methylpentanamide (3q)

The product was obtained using GP B, 5 mmol scale; yield: 1.09 g (83%); white solid; mp 82–84 °C.

¹H NMR (500 MHz, CDCl₃): δ = 7.33 (d, *J* = 8.4 Hz, 2 H), 7.22 (d, *J* = 8.4 Hz, 2 H), 6.78 (s, 1 H), 4.44 (d, *J* = 5.9 Hz, 2 H), 4.27–4.22 (m, 1 H), 1.94–1.75 (m, 3 H), 1.00 (d, *J* = 6.4 Hz, 3 H), 0.97 (d, *J* = 6.4 Hz, 3 H).

¹³C NMR (126 MHz, CDCl₃): δ = 166.1, 162.0, 135.8, 133.9, 129.3, 129.2, 57.3, 43.4, 41.6, 25.0, 22.9, 20.8.

2-Isocyano-4-methyl-N-(thiophen-2-ylmethyl)pentanamide (3r)

The product was obtained using GP B, 5 mmol scale; yield: 0.96 g (82%); white solid; mp 70–72 °C.

¹H NMR (500 MHz, CDCl₃): δ = 7.27–7.25 (m, 1 H), 7.01–6.99 (m, 1 H), 6.98–6.94 (m, 1 H), 6.79 (s, 1 H), 4.67–4.63 (m, 2 H), 4.25–4.21 (m, 1 H), 1.94–1.86 (m, 1 H), 1.78 (dd, *J* = 13.8, 5.1 Hz, 2 H), 0.99 (d, *J* = 6.5 Hz, 3 H), 0.96 (d, *J* = 6.5 Hz, 3 H).

¹³C NMR (126 MHz, CDCl₃): δ = 165.9, 162.0, 139.6, 127.2, 126.7, 125.9, 57.2, 41.5, 38.8, 25.0, 22.9, 20.9.

N-Benzyl-2-(1H-tetrazol-1-yl)acetamide (4a)

The product was obtained using GP C, 1 mmol scale; yield: 0.211 g (97%); white solid; mp 135–137 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 9.39 (s, 1 H), 8.93 (t, *J* = 5.4 Hz, 1 H), 7.36–7.26 (m, 5 H), 5.32 (s, 2 H), 4.34 (t, *J* = 5.8 Hz, 2 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 164.7, 145.2, 138.7, 128.4, 127.4, 127.1, 49.4, 42.5.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₁₀H₁₁N₅O: 217.10; found [M + Na]⁺: 240.14.

N-(4-Fluorobenzyl)-2-(1H-tetrazol-1-yl)acetamide (4b)

The product was obtained using GP C, 1 mmol scale; yield: 0.224 g (95%); white solid; mp 164–166 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 9.38 (s, 1 H), 8.93 (s, 1 H), 7.33 (dd, *J* = 8.5, 5.9 Hz, 2 H), 7.17 (t, *J* = 8.9 Hz, 2 H), 5.32 (s, 2 H), 4.32 (d, *J* = 5.8 Hz, 2 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 164.7, 162.3, 160.4, 145.2, 134.8, 134.8, 129.5, 129.4, 115.2, 115.1, 49.4, 41.8.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₁₀H₁₀FN₅O: 235.09; found [M – H]⁺: 234.13.

N-(4-Chlorobenzyl)-2-(1H-tetrazol-1-yl)acetamide (4c)

The product was obtained using GP C, 1 mmol scale; yield: 0.247 g (98%); white solid; mp 160–162 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 9.39 (s, 1 H), 8.96 (t, *J* = 5.5 Hz, 1 H), 7.41 (dd, *J* = 45.4, 5.5 Hz, 4 H), 5.33 (s, 2 H), 4.34 (d, *J* = 5.9 Hz, 2 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 165.3, 145.6, 138.2, 132.1, 129.7, 128.8, 49.9, 42.2.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₁₀H₁₀ClN₅O: 251.06; found [M – H]⁺: 249.94.

N-(1-Phenylethyl)-2-(1H-tetrazol-1-yl)acetamide (4d)

The product was obtained using GP C, 1 mmol scale; yield: 0.216 g (97%); white solid; mp 143–144 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 9.35 (s, 1 H), 8.93 (d, *J* = 7.7 Hz, 1 H), 7.38–7.25 (m, 5 H), 5.29 (s, 2 H), 4.92 (t, *J* = 7.3 Hz, 1 H), 1.41 (d, *J* = 7.0 Hz, 3 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 163.7, 145.1, 143.8, 128.4, 126.9, 126.0, 49.4, 48.5, 22.4.

SFC-MS (ESI): *m/z* calcd for C₁₁H₁₃N₅O [M]⁺: 231.11; found [M + Na]⁺: 254.16.

2-(1H-Tetrazol-1-yl)-N-(thiophen-2-ylmethyl)acetamide (4e)

The product was obtained using GP C, 1 mmol scale; yield: 0.218 g (98%); white solid; mp 153–154 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 9.38 (s, 1 H), 9.04 (t, *J* = 5.4 Hz, 1 H), 7.44 (dd, *J* = 5.1, 1.1 Hz, 1 H), 7.02–6.97 (m, 2 H), 5.29 (s, 2 H), 4.50 (d, *J* = 5.8 Hz, 2 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 164.5, 145.2, 141.2, 126.8, 126.0, 125.4, 49.3, 37.4.

SFC-MS (ESI): *m/z* calcd for C₈H₉N₅OS [M]⁺: 223.05; found [M – H]⁺: 222.00.

N-Phenethyl-2-(1H-tetrazol-1-yl)acetamide (4f)

The product was obtained using GP C, 1 mmol scale; yield: 0.198 g (86%); white solid; mp 144–145 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 9.36 (s, 1 H), 8.56 (t, *J* = 5.2 Hz, 1 H), 7.33–7.21 (m, 5 H), 5.23 (s, 2 H), 3.37 (q, *J* = 6.9 Hz, 2 H), 2.77 (t, *J* = 7.4 Hz, 2 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 164.6, 145.2, 145.1, 139.2, 128.7, 128.43, 126.3, 49.4, 40.6, 34.9.

SFC-MS (ESI): *m/z* calcd for C₁₁H₁₃N₅O [M]⁺: 231.11; found [M + H]⁺: 232.20.

N-(3,4-Dimethoxyphenethyl)-2-(1H-tetrazol-1-yl)acetamide (4g)

The product was obtained using GP C, 1 mmol scale; yield: 0.276 g (95%); white solid; mp 137–139 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 9.34 (s, 1 H), 8.50 (t, *J* = 5.3 Hz, 1 H), 6.88 (d, *J* = 8.2 Hz, 1 H), 6.82 (d, *J* = 1.9 Hz, 1 H), 6.73 (dd, *J* = 8.1, 1.9 Hz, 1 H), 5.21 (s, 2 H), 3.74 (s, 3 H), 3.71 (s, 3 H), 3.31 (t, *J* = 6.3 Hz, 2 H), 2.67 (t, *J* = 7.4 Hz, 2 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 164.5, 148.6, 147.3, 145.1, 131.5, 120.4, 112.5, 111.9, 55.5, 55.4, 49.4, 40.7, 34.5.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₁₃H₁₇N₅O₃: 291.13; found [M – H]⁺: 290.16.

***N*-(Cyclopropylmethyl)-2-(1*H*-tetrazol-1-yl)acetamide (4h)**

The product was obtained using GP C, 1 mmol scale; yield: 0.155 g (86%); white solid; mp 149–150 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 9.35 (s, 1 H), 8.53 (s, 1 H), 5.17 (s, 2 H), 2.68–2.63 (m, 1 H), 0.68–0.64 (m, 2 H), 0.46–0.43 (m, 2 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 165.6, 145.1, 49.3, 22.4, 5.6.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₈H₉N₅O: 167.08; found [M + H]⁺: 167.93.

***N*-(1-Benzylpiperidin-4-yl)-2-(1*H*-tetrazol-1-yl)acetamide (4i)**

The product was obtained using GP C, 1 mmol scale; yield: 0.269 g (90%); white solid; mp 126–128 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 9.36 (s, 1 H), 8.79 (d, *J* = 6.1 Hz, 1 H), 7.54–7.39 (m, 5 H), 5.25 (s, 2 H), 4.01 (s, 2 H), 3.74 (s, 1 H), 3.16 (d, *J* = 14.9 Hz, 2 H), 2.74 (s, 2 H), 1.90 (d, *J* = 11.4 Hz, 2 H), 1.77 (d, *J* = 11.7 Hz, 2 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 163.9, 145.1, 129.6, 128.4, 127.7, 61.0, 51.0, 49.4, 45.7, 30.2.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₁₅H₂₀N₆O: 300.17; found [M + H]⁺: 301.25.

***N*-Butyl-2-(1*H*-tetrazol-1-yl)acetamide (4j)**

The product was obtained using GP C, 1 mmol scale; yield: 0.168 g (92%); white solid; mp 132–134 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 9.35 (s, 1 H), 8.40 (s, 1 H), 5.22 (s, 2 H), 3.11 (q, *J* = 6.8 Hz, 2 H), 1.41 (quint, *J* = 7.4 Hz, 2 H), 1.30 (sext, *J* = 7.5 Hz, 2 H), 0.87 (t, *J* = 7.3 Hz, 3 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 164.4, 145.1, 145.1, 49.4, 31.0, 19.5, 13.6.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₇H₁₃N₅O: 183.11; found [M – H]⁺: 182.11.

***N*-(Prop-2-yn-1-yl)-2-(1*H*-tetrazol-1-yl)acetamide (4k)**

The product was obtained using GP C, 1 mmol scale; yield: 0.129 g (78%); white solid; mp 117–119 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 9.37 (s, 1 H), 8.92 (s, 1 H), 5.28 (s, 2 H), 3.95–3.94 (m, 2 H), 3.21 (t, *J* = 2.5 Hz, 1 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 164.5, 145.1, 80.3, 73.7, 49.2, 28.3.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₆H₇N₅O: 165.07; found [M – H]⁺: 163.90.

***N*-(2-Morpholinoethyl)-2-(1*H*-tetrazol-1-yl)acetamide (4l)**

The product was obtained using GP C, 1 mmol scale; yield: 0.177 g (74%); white solid; mp 99–101 °C.

¹H NMR (500 MHz, CDCl₃): δ = 8.87 (s, 1 H), 6.61 (s, 1 H), 5.15 (s, 2 H), 3.69 (t, *J* = 4.6 Hz, 4 H), 3.39 (q, *J* = 5.5 Hz, 2 H), 2.49 (t, *J* = 6.0 Hz, 2 H), 2.43 (t, *J* = 4.2 Hz, 4 H).

¹³C NMR (126 MHz, CDCl₃): δ = 163.4, 143.8, 67.0, 56.4, 53.3, 50.7, 36.1.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₉H₁₆N₆O₂: 240.13; found [M + H]⁺: 241.09.

1-(Pyrrolidin-1-yl)-2-(1*H*-tetrazol-1-yl)ethan-1-one (4m)

The product was obtained using GP C, 1 mmol scale; yield: 0.151 g (84%); white solid; mp 161–163 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 9.31 (s, 1 H), 5.52 (s, 2 H), 3.54 (t, *J* = 6.8 Hz, 2 H), 3.34 (t, *J* = 6.8 Hz, 2 H), 1.99–1.91 (m, 2 H), 1.87–1.79 (m, 2 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 162.9, 145.2, 49.2, 45.9, 45.1, 25.6, 23.7.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₇H₁₁N₅O: 181.10; found [M + H]⁺: 182.11.

1-(Piperidin-1-yl)-2-(1*H*-tetrazol-1-yl)ethan-1-one (4n)

The product was obtained using GP C, 1 mmol scale; yield: 0.169 g (87%); white solid; mp 189–190 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 9.29 (s, 1 H), 5.62 (s, 2 H), 3.45 (q, *J* = 5.5 Hz, 4 H), 1.60 (t, *J* = 7.7 Hz, 4 H), 1.47 (q, *J* = 5.5 Hz, 2 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 163.0, 145.3, 48.8, 45.2, 42.6, 25.7, 25.1, 23.8.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₈H₁₃N₅O: 195.11; found [M – H]⁺: 194.08.

1-Morpholino-2-(1*H*-tetrazol-1-yl)ethan-1-one (4o)

The product was obtained using GP C, 1 mmol scale; yield: 0.169 g (86%); white solid; mp 133–135 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 9.30 (s, 1 H), 5.65 (s, 2 H), 3.66 (t, *J* = 4.6 Hz, 2 H), 3.59 (t, *J* = 4.7 Hz, 2 H), 3.52 (t, *J* = 4.9 Hz, 2 H), 3.46 (t, *J* = 5.0 Hz, 2 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 163.7, 145.3, 145.3, 65.9, 65.8, 48.7, 44.7, 42.0.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₇H₁₁N₅O: 197.09; found [M – H]⁺: 196.31.

1-(4-Benzylpiperazin-1-yl)-2-(1*H*-tetrazol-1-yl)ethan-1-one (4p)

The product was obtained using GP C, 1 mmol scale; yield: 0.207 g (72%); white solid; mp 92–94 °C.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 9.30 (s, 1 H), 7.36–7.26 (m, 5 H), 5.63 (s, 2 H), 3.52 (t, *J* = 8.4 Hz, 4 H), 3.47 (s, 2 H), 2.46 (s, 2 H), 2.36 (s, 2 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 163.3, 145.3, 128.9, 128.3, 127.1, 61.8, 52.4, 51.9, 48.7, 44.2, 41.7.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₁₄H₁₈N₆O: 286.15; found [M + H]⁺: 287.16.

***N*-(4-Chlorobenzyl)-4-methyl-2-(1*H*-tetrazol-1-yl)pentanamide (4q)**

The product was obtained using GP C, 1 mmol scale; yield: 0.228 g (74%); clear liquid.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 9.63 (s, 1 H), 9.10 (t, *J* = 5.7 Hz, 1 H), 7.39 (d, *J* = 8.5 Hz, 2 H), 7.27 (d, *J* = 8.5 Hz, 2 H), 5.58–5.54 (m, 1 H), 4.30 (s, 2 H), 2.19–2.12 (m, 1 H), 1.99–1.92 (m, 1 H), 1.25–1.15 (m, 1 H), 0.88 (d, *J* = 5.2 Hz, 3 H), 0.86 (d, *J* = 5.2 Hz, 3 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 167.9, 144.1, 144.1, 138.0, 132.1, 129.7, 128.8, 60.4, 55.4, 42.4, 24.9, 22.8, 21.7.

SFC-MS (ESI): *m/z* [M]⁺ calcd for C₁₄H₁₈ClN₅O: 307.12; found [M – H]⁺: 305.92.

4-Methyl-2-(1H-tetrazol-1-yl)-N-(thiophen-2-ylmethyl)pentanamide (4r)

The product was obtained using GP C, 1 mmol scale; yield: 0.193 g (69%); clear liquid.

^1H NMR (500 MHz, CDCl_3): δ = 8.94 (s, 1 H), 7.58 (t, J = 5.7 Hz, 1 H), 7.21–7.15 (m, 1 H), 6.96–6.86 (m, 2 H), 5.48 (t, J = 7.9 Hz, 1 H), 4.68–4.51 (m, 2 H), 2.05 (t, J = 7.5 Hz, 2 H), 1.37–1.28 (m, 1 H), 0.89 (d, J = 4.2 Hz, 3 H), 0.87 (d, J = 4.2 Hz, 3 H).

^{13}C NMR (126 MHz, CDCl_3): δ = 167.2, 142.2, 139.6, 127.1, 126.5, 125.6, 61.3, 42.1, 38.8, 24.7, 22.5, 21.6.

SFC-MS (ESI): m/z $[\text{M}]^+$ calcd for $\text{C}_{12}\text{H}_{17}\text{N}_5\text{OS}$: 279.12; found $[\text{M} - \text{H}]^+$: 278.33.

Acknowledgment

The research leading to these results has received support from the NIH (1R01GM097082) and from the Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115489. These resources are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007–2013) and EFPIA companies' in-kind contribution. Y.W. acknowledges a CSC stipendship.

Supporting Information

Supporting information for this article is available online at <http://dx.doi.org/10.1055/s-0035-1562435>.

References

- (1) These authors contributed equally to this article.
- (2) Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. *Nucleic Acids Res.* **2000**, *28*, 235.
- (3) (a) Herr, R. J. *Bioorg. Med. Chem.* **2002**, *23*, 2699. (b) Matta, C. F.; Arabi, A. A.; Weaver, D. F. *Eur. J. Med. Chem.* **2010**, *45*, 1868.
- (4) Murray, C. W.; Rees, D. C. *Angew. Chem. Int. Ed.* **2016**, *55*, 488.
- (5) Hoekstra, W. J.; Hargrove, T. Y.; Wawrzak, Z.; da Gama Jaen Batista, D.; da Silva Cristiane, F.; Nefertiti, A. S. G.; Rachakonda, G.; Schotzinger, R. J.; Villalta, F.; Soeiro, M. C.; Lepesheva, G. I. *Antimicrob. Agents Chemother.* **2016**, *60*, 1058.
- (6) Chen, Y.; Shoichet, B. K. *Nat. Chem. Biol.* **2009**, *5*, 158.
- (7) (a) Wang, K.; Nguyen, K.; Huang, Y.; Dömling, A. *ACS. Comb. Sci.* **2009**, *11*, 920. (b) Dömling, A.; Beck, B.; Fuchs, T.; Yazbak, A. *ACS Comb. Sci.* **2006**, *8*, 872.
- (8) Finnegan, W. G.; Henry, R. A.; Lofquist, R. J. *Am. Chem. Soc.* **1958**, *80*, 3908.
- (9) (a) Mani, P.; Singh, A. K.; Awasthi, S. K. *Tetrahedron Lett.* **2014**, *55*, 1879. (b) Gawande, S. D.; Raihan, M. J.; Zanzwar, M.; Kavala, V.; Janreddy, D.; Kuo, C. W.; Chen, M. L.; Kuo, T. S.; Yao, C. F. *Tetrahedron* **2013**, *69*, 1841. (c) Gawande, S. D.; Raihan, M. J.; Zanzwar, M. R.; Kavala, V.; Janreddy, D.; Kuo, C. W.; Chen, M. L.; Kuo, T. S.; Yao, C. F. *Tetrahedron* **2013**, *69*, 1841. (d) Das, B.; Reddy, C. R.; Kumar, D. N.; Krishnaiah, M.; Narender, R. *Synlett* **2010**, 391. (e) Yoneyama, H.; Usami, Y.; Komeda, S.; Harusawa, S. *Synthesis* **2013**, *45*, 1051. (f) Roh, J.; Artamonova, T. V.; Vávrová, K.; Koldobskii, G. I.; Hrabálek, A. *Synthesis* **2009**, 2175. (g) Vorona, S.; Artamonova, T.; Zevatskii, Y.; Myznikov, L. *Synthesis* **2014**, *46*, 781. (h) Cantillo, D.; Gutmann, B.; Kappe, C. O. *J. Am. Chem. Soc.* **2011**, *133*, 4465.
- (10) Kappe, C. O.; Stadler, A.; Dallinger, D. *Microwaves in Organic and Medicinal Chemistry*, In *Methods and Principles in Medicinal Chemistry*; Vol. 52; Mannhold, R.; Kubinyi, H.; Folkers, G., Eds.; Wiley-VCH: Weinheim, **2012**, 487.
- (11) Oliveri-Mandala, E.; Alagna, B. *Gazz. Chim. Ital.* **1910**, *40* (II), 441.